Manufacturing News of Note–GlaxoSmithKline strikes a deal for manufacturing T cells

Inn this week's news of note stories about GlaxoSmithKline, Samsung and Recipharm. (Pixabay)

> GlaxoSmithKline has struck a deal with Hitachi Chemical Advanced Therapeutics Solutions to manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials. Release

> Recipharm has completed its $60 million buyout of Sanofi’s contract inhalation drug business and plant in the U.K. Release

> South Korean CDMO Samsung BioLogics has started production of its Plant 3, what it is referring to as the world’s largest single bio manufacturing plant. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.